Trauma is the leading cause of death and disability in children in the United States. The objective of this study is to evaluate the benefits and harms of tranexamic acid (TXA; a drug that stops bleeding) in severely injured children with hemorrhagic brain and/or torso injuries. Using thromboelastography, we will measure baseline fibrinolysis to assess for treatment effects of TXA at different levels of fibrinolysis.

Start Date01 Oct 2026

Sponsor / Collaborator

University of California, Davis

CTRI/2025/11/097287

/ Not yet recruitingPhase 2/3IIT

Efficacy of feracrylum and tranexamic acid as topical hemostatic agent in patients taking oral antiplatelets undergoing dental extraction - NIL

Start Date28 Dec 2025

Sponsor / Collaborator-

100 Clinical Results associated with Tranexamic Acid

100 Translational Medicine associated with Tranexamic Acid

100 Patents (Medical) associated with Tranexamic Acid

8,527

Literatures (Medical) associated with Tranexamic Acid

01 Feb 2026·JOURNAL OF CRITICAL CARE

Impact of different preferred functional outcomes on the results of the pre-hospital antifibrinolytics for traumatic coagulopathy and hemorrhage (PATCH-trauma) trial

Article

Author: Gartner, Dashiell C ; McArthur, Colin J ; Young, Paul J ; Forbes, Andrew B ; Mitra, Biswadev ; Burns, Brian ; Maegele, Marc ; Bernard, Stephen A ; Gruen, Russel L ; Zampieri, Fernando G

RATIONALE:

Ordinal endpoints offer more detailed outcome assessment than mortality, though some disabilities may be considered worse than death by patients.

OBJECTIVES:

To evaluate how different Glasgow Outcome Scale - Extended (GOS-E) hierarchical structures affect effect estimation in the PATCH-Trauma trial.

METHODS:

This post-hoc analysis of the PATCH-Trauma trial compared pre-hospital tranexamic acid (TXA) to placebo in severely injured patients at risk of acute traumatic coagulopathy. The study included patients with complete 6-month outcomes. Using generalized pairwise comparisons, researchers analyzed the 8-point GOS-E, ICU length-of-stay, and thromboembolic complications. Results were reported using win ratio (WR) statistics, with values above one favoring TXA. The analysis explored GOS-E with mortality rankings adjusted based on different outcomes being considered worse than death.

MAIN RESULTS:

The study included 1107 patients (546 placebo, 561 TXA). Original GOS-E results showed a neutral WR (1.03; 95 % CI 0.90-1.19). When death was considered preferable to progressively less impaired functionality (from vegetative state to upper moderate disability), the WR decreased to 0.86 (95 % CI 0.75-1.00).

CONCLUSION:

The assessment of TXA therapy's efficacy and safety may vary depending on scenarios where certain functional outcomes are considered worse than death. This analytical approach could inform functional outcome assessment in future acute care trials.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of injectable sodium hyaluronate with vitamin C, tranexamic acid, and glutathione for pigmented dark circles

Article

Author: Zhuang, Jun ; Zhang, Ziming ; Liang, Yutong ; Zou, Muyan ; Su, Xueshang ; Lu, Shunbing ; Hu, Jintian ; Guo, Fengfeng

BACKGROUND:

Periorbital hyperpigmentation (POH) is a common benign condition affecting facial esthetics. This study evaluated the efficacy and safety of an injectable sodium hyaluronate complex solution combined with vitamin C, tranexamic acid, and glutathione for POH treatment.

METHOD:

120 POH patients were randomly divided into two groups. All participants received two treatment injections at two-week intervals. Evaluations were conducted at 4 and 12 weeks posttreatment, assessing periorbital grayscale values, clinical grading changes, Global Esthetic Improvement Score, Dermatologic Quality of Life Index (DLQI), and patient satisfaction.

RESULT:

The treatment group demonstrated significant improvements in grayscale values (162.10 ± 14.22 to 169.66 ± 13.43) and reduced pigmentation differences from normal skin (23.01 ± 12.73 to 14.44 ± 14.79). The control group showed no significant changes. Treatment group patients exhibited significantly better grayscale values (p < .05), improved DLQI scores, and reduced dark circle severity (p < .05). 96.7% of treated patients reported satisfaction with visible esthetic improvements.

CONCLUSION:

The hyaluronate-based combination therapy effectively improved POH, demonstrating significant esthetic enhancement and quality of life improvement. This minimally invasive approach proved safe, effective, and highly satisfactory, presenting a promising treatment option for periorbital hyperpigmentation.

EVIDENCE LEVEL:

Level II.

01 Dec 2025·LUNG

Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis–A Systematic Review and Meta-Analysis

Review

Author: Krishnamoorthy, Yuvaraj ; Salih, Anas ; Elanjeran, Rajkumar ; Rajendran, Gunaseelan ; Dinesh, Vasudha ; Ramkumar, Anitha ; Kannan, Rahini ; Mahalingam, Sasikumar ; Thirthar Palanivelu, Elamurugan ; Ponnaeasu, Sathya Prakasham

BACKGROUND:

Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes. Inhalational administration has garnered interest because of its targeted action and minimal systemic effects. This study aimed to assess the effectiveness of inhalational TXA in nonmassive hemoptysis.

METHODS:

A systematic literature search encompassing PubMed Central, EMBASE, SCOPUS, and ProQuest was conducted. Randomized controlled trials (RCTs) and observational studies assessing the effectiveness of inhalational tranexamic acid for nonmassive hemoptysis were included. Comparative intervention effect estimates from meta-analyses are reported as pooled odds ratios and pooled mean differences with 95% confidence interval (CI).

FINDINGS:

Analysis of three RCTs and two observational studies, comprising 351 patients (192 cases and 159 controls), revealed varying risk levels of bias across the studies. Nebulized tranexamic acid was 3.85 times more likely to achieve hemoptysis cessation than alternative treatments across all RCTs. Moreover, patients receiving nebulized tranexamic acid required fewer (43%) pulmonary interventional procedures than those receiving other treatments. Despite showing a trend towards reducing posttherapy bleeding (20 ml less), conclusive results were hindered by wide CI, necessitating further investigation.

INTERPRETATION:

Nebulized tranexamic acid may be a potential therapeutic option for nonmassive hemoptysis. While our analysis suggests its potential benefits in halting bleeding and reducing the need for invasive procedures, the quality of the available evidence is limited due to the risk of bias and study limitations. This underscores the necessity for additional randomized controlled trials with larger sample sizes and rigorous study designs to strengthen evidence and optimize clinical utility.

PROSPERO REGISTRATION:

The registration for this systematic review and meta-analysis was completed through Prospero on January 30, 2024, with the registration number CRD42024501624.

110

News (Medical) associated with Tranexamic Acid

21 Oct 2025

·www.einpresswire.com

FDA Provides Update to Health Care Professionals About Risk of Inadvertent Intrathecal (Spinal) Administration of Tranexamic Acid Injection

FDA is requiring labeling changes to strengthen the warnings that tranexamic acid injection should be administered only intravenously (into the vein). Tranexamic acid injection products are not to be administered intrathecally (into the spine) or as an epidural injection. FDA is taking this action after having identified and evaluated medication error cases of inadvertent neuraxial (intrathecal or epidural) administration of tranexamic acid. In these cases, tranexamic acid was erroneously administered neuraxially instead of the intended local anesthetic (e.g., bupivacaine, lidocaine, mepivacaine, and ropivacaine), which resulted in serious patient outcomes, including prolonged hospitalization and death. Medical practice-level and facility-level human factors (e.g., storing tranexamic acid injection close to local anesthetics and failing to verify the product before administration) contributed to the medication errors. Tranexamic acid injection is indicated for short-term use (2 to 8 days) in patients with hemophilia to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Health care professionals should only administer tranexamic acid injection by the intravenous route. Tranexamic acid injection is supplied in single-dose ampules and single-dose vials containing 1,000 mg tranexamic acid in 10 mL and is marketed both under the proprietary name, Cyklokapron, and as a generic drug. Tranexamic acid is also supplied in sodium chloride injection in single-dose bags containing 1,000 mg of tranexamic acid in 100 mL solution for intravenous use. FDA is requiring the following changes to the prescribing information for tranexamic acid injection: Add a Boxed Warning to communicate the risk of medication errors involving inadvertent neuraxial administration of tranexamic acid injection Add a statement to indicate that tranexamic acid injection is contraindicated as a neuraxial injection Update the Dosage and Administration section to clarify that tranexamic acid injection is only to be administered intravenously and to provide instructions for preparing and administering the diluted solution Additionally, FDA is recommending that the container labels for tranexamic acid injection prominently display the product name and intravenous route of administration. Health care professionals should consider the following steps to minimize the risk of inadvertent neuraxial administration of tranexamic acid injection: Storage Do not store tranexamic acid injection vials or ampules near local anesthetics or in kits containing local anesthetics intended for spinal or epidural anesthesia. Store medication vials in a way that makes the labels visible to avoid reliance on identifying drugs by the vial cap color. Use barcode scanning when stocking medication cabinets to ensure the correct medication is placed in the appropriate storage bin. Store tranexamic acid injection vials and ampules in separate carts outside the operating room or in locked bins that require barcode scanning to remove from the bin. Administration Use commercially available or pharmacy-prepared intravenous infusion bags of tranexamic acid, when possible, to minimize confusion with local anesthetics supplied in vials or ampules. Use barcode scanning and always check the container label to ensure the correct product is selected and administered. If withdrawing tranexamic acid injection from a vial or ampule, promptly label each syringe when it is prepared unless it is immediately administered. If using pre-packaged spinal or epidural kits, carefully inspect the container labels of medications included in the kit to verify the intended medication before use. Additional Recommendations for Health Care Facilities Add a prominent "contains tranexamic acid" auxiliary warning label to all vials and ampules that contain tranexamic acid injection. Add tranexamic acid injection to internal high-alert medication lists and develop procedures and policies to ensure safe use and minimize the risk of mix-up with other medications. FDA encourages health care professionals and patients to report adverse events, medication errors, and product quality problems experienced with the use of any medical product to MedWatch: The FDA Safety Information and Adverse Event Reporting Program : Complete and submit the report online at www.fda.gov/medwatch/report.htm ; or Download and complete the form , then submit it via fax at 1-800-FDA-0178. Content current as of: 10/21/2025 Regulated Product(s) Topic(s) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

09 Sep 2025

·www.einpresswire.com

A.forall expands US generics portfolio

Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach By integrating this portfolio with our existing capabilities, we focus to reach further into markets where high-quality generic medicines make the greatest difference,” — Steen Vangsgaard ANDERLECHT, BRUSSELS, BELGIUM, September 9, 2025 / EINPresswire.com / -- A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With this acquisition, A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s sharpened focus on high-quality generics worldwide. Strengthening Essential Healthcare The acquired portfolio includes four well-established hospital products that address critical therapeutic needs: • Dihydroergotamine Mesylate (neurology – for the treatment of migraine and cluster headaches) • Piperacillin/Tazobactam (infectious disease – broad-spectrum antibiotic for hospital-acquired infections) • Tranexamic Acid (hematology – to control bleeding in surgical and trauma settings) • Phenylephrine Hydrochloride (anesthesiology – to manage hypotension during surgery) These medicines are widely integrated in US hospital protocols and marketed via established pharmaceutical distributors and group purchasing organizations, ensuring strong clinical familiarity among healthcare professionals. The newly acquired products will be commercialized through A.forall’s US subsidiary, Milla Pharmaceuticals Inc . The two late-stage pipeline products target complementary therapeutic areas and are expected to launch in the coming years. Steen Vangsgaard, CEO of A.forall, comments: “This acquisition fits perfectly with our renewed strategy to develop, commercialize and add value to medicines, increasing their availability where they matter most. These products expand our US relevance and give us immediate access to a robust portfolio that meets essential therapeutic needs. It’s a strategic investment that delivers scale, diversification and valuable cross-selling opportunities.” Strategic US Focus For A.forall, the US is a strategic priority. With a dedicated team on the ground, strong partnerships and a robust pipeline, the company continues to invest in one of the world’s most competitive and complex healthcare environments. Since 2017, six products of A.forall were registered successfully in the US market, demonstrating consistent growth and commitment to American healthcare providers. "By integrating this portfolio with our existing capabilities, we focus to reach further into markets where high-quality generic medicines make the greatest difference," Vangsgaard adds. "This acquisition strengthens our brand recognition and significantly expands our commercial presence in the world's largest pharmaceutical market." This acquisition follows the recent decision to divest A.forall's Retail & Hospital division and focus entirely on generics: a strategy that gives the company a sharper scope, stronger momentum and a clear direction for growth. About A.forall A.forall is a Belgian pharmaceutical group with headquarters in Anderlecht and offices in Ireland and the United States. At current, the company employs over 144 people and distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. A.forall is also a global player in the generics market, now with 35+ molecules on the European and U.S. market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas. Driven by one mission #MakingAffordableMedicinesAvailableToAll, A.forall focuses 100% on the development, licensing and commercialization of generic medicines worldwide. A.forall is part of The Riverside Company's portfolio, a global investment firm focused on the smaller end of the middle market that has invested in more than 220 healthcare companies since 1988. For more information, visit: www.aforallpharma.com . We’re happy to provide additional context or answer any questions you may have. For media inquiries or more information, please contact: A.forall Group NV Communication Department A.forall +32 2 526 64 14 communications@aforallpharma.com Visit us on social media: LinkedIn Steen Vangsgaard on the US expansion Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Acquisition

10 Jul 2025

·www.einpresswire.com

Antifibrinolytic Drugs Market to Hit $19.3 Billion by 2026 Amid Rising Demand for Hemorrhage Control

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. PORTLAND, OR, UNITED STATES, July 10, 2025 / EINPresswire.com / -- The Antifibrinolytic Drugs Market size was estimated at $13.59 billion in 2018 and is expected to hit at $19.33 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026. The report provides a detailed analysis of the market size & estimations, top investment pockets, top winning strategies, drivers & opportunities, competitive scenario, and wavering market trends. ► Don't Miss Out “Download Your Exclusive Sample PDF Report” Now: https://www.alliedmarketresearch.com/request-sample/6279 Antifibrinolytics are one of the most commonly used drugs to prevent fibrinolysis by blocking the activation of plasminogen proenzyme and plasmin. This intervention is critical to avoid clotting in areas that are prone to fibrinolysis such as the oral cavity, nasal cavity and female genitalia. Recommended antifibrinolytic drugs include Epsilon aminocaproic acid, tranexamic acid, Amicar, aminocaproic acid, aprotinin, and Cyklokapron. Also, these drugs find their application in surgery such as heart surgery, neurosurgeries and dental surgery. In addition, women use antifibrinolytic drugs to control heavy menstruation. Major market players covered in the report, such as - Akorn Inc., Aurobindo Pharma Limited, Bayer AG, Ferring Holding SA, Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vitruvias Therapeutics Inc. Key Benefits for Stakeholders - • The report provides quantitative analysis of market segments, current trends, strategies and potential of antifibrinolytic drugs market research to identify potential antifibrinolytic drugs market opportunities in genetics. • In-depth analysis of this sector helps identify current market opportunities. • Market analysis and information related to key drivers, restraints and opportunities are provided. • Porter's Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers. • The largest countries in each region are listed according to their contribution to the global market. • Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation. • The report includes regional and global antifibrinolytic drugs market analysis, key players, market segments, application areas and Market growth strategies. ★ Procure Complete Report [ 220 Pages PDF with Insights, Charts, Tables, and Figures ] @ https://www.alliedmarketresearch.com/request-for-customization/6279 Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. TABLE OF CONTENT - CHAPTER 1 - INTRODUCTION: 1.1. Report description 1.2. Key market segments 1.3. List of key players profiled in the report 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models CHAPTER 2 - EXECUTIVE SUMMARY: 2.1. Key findings of the study 2.2. CXO Perspective CHAPTER 3 - MARKET OVERVIEW: 3.1. Market Definition and Scope 3.2. Key Findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. Market Share Analysis/Top Player Positioning 3.4. Porter’s Five Forces Analysis 3.5. Market Dynamics 3.5.1. Drivers 3.5.2. Restraints 3.5.3. Opportunities… 3.6. COVID-19 Impact Analysis on the market North America accounted for the largest share of the antifibrinolytic drugs market in 2018 and is expected to continue this trend during the forecast period. This is due to the increasing number of women using these drugs to control heavy periods. Additionally, a significant increase in surgeries in this region is driving the market growth. However, the Asia-Pacific region is expected to experience rapid growth due to the rise in road accidents and the increase in the use of these drugs by women to control menstrual cycle. 👉 For Purchase Inquiry of Report: https://www.alliedmarketresearch.com/purchase-enquiry/6279 The antifibrinolytic drugs market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global antifibrinolytic drugs market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models. Frequently Asked Questions? Q1. What is the total market value of antifibrinolytic drugs market report? Q2. Which are the top companies holding the market share in antifibrinolytic drugs market? Q3. Which are the largest regions for this Market? Q4. What is the leading technology of antifibrinolytic drugs market? Q5. What are the major drivers for this specific Market? Q6. What are the upcoming key trends in the antifibrinolytic drugs market report? About Us - Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa Allied Market Research + +1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Tranexamic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D01136	Tranexamic Acid	B02AA02	DB00302

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Menorrhagia	United States	Amring Pharmaceuticals SA	13 Nov 2009
Hemophilia	United States	Pharmacia & Upjohn, Inc.	30 Dec 1986
Hemophilia	United States	Pfizer Inc.	30 Dec 1986
Erythema	Japan	Nipro Pharma Corp.	16 Jan 1969
Pruritus	Japan	Nipro Pharma Corp.	16 Jan 1969
Tumescence	Japan	Nipro Pharma Corp.	16 Jan 1969
Drug Eruptions	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Hemorrhage	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Pharyngolaryngitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Stomatitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Tonsillitis	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965
Urticaria	Japan	Daiichi Sankyo Co., Ltd.	31 Aug 1965

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intestinal Diseases	Phase 3	China	Hengyi Biopharmaceutical (Shanghai) Co., Ltd.	27 Mar 2023
Ileus	Phase 3	United States	Palisade Bio, Inc.	28 Jun 2022
Gastrointestinal dysfunction	Phase 3	China	Hengyi Biopharmaceutical (Shanghai) Co., Ltd.	30 Jan 2022
Cerebral Hemorrhage	Phase 3	Nepal	-	08 Feb 2021
Hematoma	Phase 3	Nepal	-	08 Feb 2021
Spinal fusion	Phase 3	United States	Exela Pharma Sciences LLC	17 Oct 2018
Colonic Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Hepatocellular Carcinoma	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Pancreatic Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012
Stomach Cancer	Phase 3	Nepal	Pfizer Inc.	01 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04344860 (VWD-Woman, Pubmed \| Blood Adv)	Phase 3	Von Willebrand Disease, Type 1	20	Tranexamic acid + recombinant VWF	dvsvnbnhxc(yugkhywklc): P-Value = 0.49 View more	Negative	09 Dec 2025
				Recombinant VWF
NCT05075200 (TXA-Dosing, CTgov)	Phase 2	-	21	tranexamic acid (Group I)	pumrtyqkft(knvxaeuxrq) = pxcgtzhkis cuamswfhtw (csrmntpihm, 21.0) View more	-	09 Dec 2025
				tranexamic acid (Group II)	pumrtyqkft(knvxaeuxrq) = bxolxsankm cuamswfhtw (csrmntpihm, 23.9) View more
NCT04803747 (TRACTION, ASH2025)	Phase 4	-	8,273	Tranexamic acid	uksxzspbgk(askwyntdmx) = dsorfukpnd zwbvoqwmaa (sbkueothvk ) View more	Positive	06 Dec 2025
				Placebo	uksxzspbgk(askwyntdmx) = cpziffytqn zwbvoqwmaa (sbkueothvk ) View more
NCT05441592 (CTgov)	Phase 4	Hematoma	107	Tranexamic acid injection (Irrigation that contains tranexamic acid (TXA))	ylknstemko = mfqtqlvozn nudbkyifqm (ziyuevnvkp, yxdvsvkffl - vgygyohpgu) View more	-	26 Nov 2025
				No additional irrigation (No additional irrigation usual care)	ylknstemko = fcynoqdnbd nudbkyifqm (ziyuevnvkp, flxkwlquzi - bpveciwkqm) View more
NCT04344860 (VWD Woman Trial \| VWD-Woman, CTgov)	Phase 3	Von Willebrand Diseases	20	Recombinant Von Willebrand factor+Tranexamic Acid Injection [Cyklokapron] (rVWF plus TA)	znheduuhbe(glnyjemovq) = dsimkcenxg yqcwxuzhio (wgxkyuhnik, 802.5) View more	-	31 Oct 2025
				Recombinant Von Willebrand factor (rVWF alone)	znheduuhbe(glnyjemovq) = cpgycygvmh yqcwxuzhio (wgxkyuhnik, 355.08) View more
NCT03136445 (TREATT, CTgov)	Phase 3	Hemorrhage \| Thrombocytopenia \| Hematologic Neoplasms ... View more	616	TXA (Intervention Arm)	olwblzokrc = hmgollbyzt tpdcqxaccx (vbvawcxgyw, ryuwxgfgpz - zklwjcxtkr) View more	-	28 Oct 2025
				Placebo (Control Arm)	olwblzokrc = awzodnyeer tpdcqxaccx (vbvawcxgyw, wwkqibueam - cnvqffobrp) View more
NCT05807074 (CTgov)	Phase 4	Hematoma \| Seroma \| Breast Cancer	23	Saline+Tranexamic Acid	pklumvxrtt = arlyucyftz jwamkgkkhu (jcgiirxjoi, mqixzerumm - aiiqqiuyhc) View more	-	29 Sep 2025
NCT04272606 (Pubmed \| BJA Open)	Phase 2	Delirium cytokines \| S100B	-	Tranexamic acid (TXA)	gytfyhjfjg(pdedxdqlxj) = hqwccphwqv rglkjdskkc (jmhiwfxlrr ) View more	Positive	01 Jun 2025
				Placebo	gytfyhjfjg(pdedxdqlxj) = wizqofczfs rglkjdskkc (jmhiwfxlrr ) View more
NCT04347122 (CTgov)	Phase 4	Musculoskeletal Diseases \| Soft Tissue Sarcoma	12	TXA (Bony Tumor w/ TXA Group)	pcfiredphb(prcmsbtipf) = ijbwkbkdry awzhksmrez (sorjfkkszh, mkfpykvfed - wkqcqxwtqw) View more	-	21 May 2025
				TXA (Bony Tumor no TXA Group)	ngsaiiupsc(shxppkneqc) = jycumedcgv wvlzewpgtn (nkkquigsvc, xptsxvzuht - jotmajqruk) View more
NCT03505723 (POISE-3, Pubmed \| JAMA Surg)	Phase 3	-	9,535	Tranexamic Acid	prqjiznbrf(auhnqplfzq): HR = 0.74 (95% CI, 0.59 - 0.93) View more	Positive	01 Mar 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tranexamic Acid

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation